Asparkam - instructions for use, dose, side effects, contraindications

magnesium aspartate tetrahydrate 175 mg ("Magnesium DL-asparginate (racemic) "potassium asparaginate hemihydrate -175 mg (" Potassium DL-asparginate (racemic) " Excipients:

potato starch, corn starch, talc, calcium stearate

or asparks, semi-finished product-490 mg, which corresponds to

active substances:

magnesium asparaginate - 175 mg;

potassium asparaginate - 175 mg;

Excipients: potato starch, talcum, calcium stearate.

Description:

Tablets are white or almost white in color, flat-cylindrical, with a facet and a risk.

Pharmacotherapeutic group:Potassium and magnesium preparation

ATX: & nbsp

A.12.C.X Preparations of other minerals

Pharmacodynamics:

Asparta is a source of potassium and magnesium ions, regulates metabolic processes. The mechanism of action is presumably associated with the role of aspartate as a carrier of magnesium and potassium ions in the intracellular space and with the participation of aspartate in metabolic processes.Thus, asparks eliminates the imbalance of electrolytes, reduces the excitability and conductance of the myocardium (moderate antiarrhythmic effect).

Pharmacokinetics:Easily absorbed when ingested and relatively quickly excreted by the kidneys.

Indications:

Asparks are used in complex therapy for heart failure, coronary heart disease, hypokalemia, heart rhythm disturbances (including, with myocardial infarction, cardiac glycosides overdose).

Contraindications:

Hypersensitivity to the drug, a violation of the exchange of amino acids, arterial hypotension. Acute and chronic renal failure, hyperkalemia, hypermagnesia, violation of atrioventricular conduction (AV blockade I-III st.), severe myasthenia gravis, acute metabolic acidosis, dehydration (exicosis), hemolysis, Addison's disease, oliguria, anuria.

Carefully:In pregnancy and lactation, in the presence of hypophosphatemia, urolithic diathesis (associated with a violation of the exchange of Ca2 +, Mg2+ and ammonium phosphate).

Pregnancy and lactation:Carefully.

Dosing and Administration:

Aspartame is prescribed inside, after eating.

Prescribe usually adults 1-2 tablets 3 times a day. The course of treatment is 3-4 weeks.

If necessary, repeat the course.

Side effects:

Nausea, vomiting, diarrhea, pain in the epigastric region (in patients with an anatomic gastritis or cholecystitis), atrioventricular blockade, a paradoxical reaction (an increase in the number of extrasystoles), hyperkalemia (nausea, vomiting, diarrhea, paresthesia) and hypermagnia (hyperemia of the face, thirst , bradycardia, lowering blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions).

Overdose:

Symptoms: hyperkalemia and hypermagnia.

Treatment: intravenously calcium chloride; if necessary, hemodialysis and peritoneal dialysis.

Interaction:

Pharmacodynamic: joint application with potassium-sparing diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, ACE inhibitors, non-steroidal anti-inflammatory drugs increases the risk of hyperkalemia up to the development of arrhythmia and asystole. The use of potassium preparations together with glucocorticosteroids eliminates the hypokalemia caused by the latter.Under the influence of potassium, undesirable effects of cardiac glycosides decrease. Magnesium reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin. Anesthetics increase the oppressive effect of magnesium preparations on the central nervous system; with the simultaneous use with with atrakury without id atom, decamethonium bromide and suxamethonium, neuromuscular blockade may be strengthened; calcitriol increases the content of magnesium in blood plasma, calcium preparations reduce the effect of magnesium preparations.

Strengthens the negative dromo- and batmotropic effect of antiarrhythmic drugs.

Pharmacokinetic: astringents and enveloping agents reduce the absorption of the drug in the gastrointestinal tract.

Special instructions:

It is necessary to constantly monitor the electrolytic homeostasis.

Form release / dosage:

Pills.

Packaging:

For 10, 20 or 50 tablets in a contour cell package.

For 30, 50 or 100 tablets in cans of polymer.

1,2, 3, 4, 5 contour packs or one jar together with the instruction for use will be prevented in a pack of cardboard.

It is allowed to place contiguous mesh packages with an equal number of instructions placed in a group package.

Storage conditions:

Store at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life:

4 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:Without recipe

Registration number:LS-001237

Date of registration:05.03.2010 / 17.05.2013

Expiration Date:Unlimited

The owner of the registration certificate:PHARMSTANDART-FORESTRY, OJSC PHARMSTANDART-FORESTRY, OJSC Russia

Manufacturer: & nbsp

PHARMSTANDART-FORESTRY, OJSC Russia

Information update date: & nbsp17.05.2013

Illustrated instructions

Instructions

Aspark (Asparcam)